Michael Yee

Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. But, the biotech company, renowned for its cancer and HIV treatments, has not positioned itself as a contender in this lucrative field. Most recently,...

Shares of Moderna Inc (NASDAQ: MRNA) rallied in premarket trading on Monday. While the COVID-19 story has become old, a new candidate in Moderna’s pipeline is likely to be a catalyst for its stock, according to Jefferies. The Moderna Analyst: Michael Yee upgraded Moderna from Hold to Buy...

Shares of coronavirus vaccine maker Moderna Inc. (NASDAQ: MRNA) were rallying in premarket trading on Monday. What Happened: Jefferies analyst Michael Yee upgraded shares of Moderna from Neutral to Buy and raised the price target from $170 to $275, suggesting 42% upside from current levels....

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-stage biopharma following FDA approval of its antibody-drug conjugate Trodelvy as a third-line treatment for metastatic triple-negative...

Moderna Inc (NASDAQ: MRNA) initiated a large-scale Phase 3 study of its coronavirus vaccine candidate in mid-July. An analyst at Jefferies conducted a statistical analysis of the study design to arrive at the likely timing of the data readout — whether they think the study will achieve...

Moderna Inc (NASDAQ: MRNA) shares are surging above the $70 level for the first time since late May following sell-side commentary on its coronavirus vaccine program. The Moderna Analyst: Jefferies analyst Michael Yee initiated coverage of Moderna with a Buy rating and $90 price target. The...

Shares of the mid-cap biotech Amarin Corporation plc (NASDAQ: AMRN) were pulling back to their lowest level since early January on Friday. What Happened Amarin said Thursday after the market close that it was notified by the FDA of the agency's intention to hold an Adcom meeting for...

The new year has brought relief to Gilead Sciences, Inc. (NASDAQ: GILD)’s long-pressured stock, and one analyst projects a continuation in its U-shaped recovery. The Rating Jefferies analyst Michael Yee upgraded Gilead to Buy and raised the price target from $87 to $95. The Thesis...

Analysts at Jefferies hosted a fireside chat-themed conversation with Spark Therapeutics Inc (NASDAQ: ONCE) to discuss the company's successes from Thursday's FDA panel. Analyst Michael Yee maintains a Buy rating on Spark's stock with an unchanged $95 price target and noted three main...

Michael Yee of RBC Capital Markets reiterated an Outperform rating on Kite Pharma Inc (NASDAQ: KITE) with a price target boosted to $95 from a previous $85. According to Yee, competition from Novartis AG (ADR)'s (NYSE: NVS) CTL019 CAR-T isn't too concerning as Novartis' prior studies...

There’s no question it has been a rough few months for biotech investors. In a new report, RBC Capital Markets analyst Michael Yee looked at whether the biotech sector has endured similar selloffs in the past. According to Yee, the biotech sector has dropped below its current forward PE...

Michael Yee of RBC Capital Markets commented in a note that M&A activity within small- and mid-cap healthcare companies "doesn't seem to be slowing down much." Yee added that "good" late-stage and de-risked drugs should command a high value, regardless of any political uncertainty. The latest...

Following the recently-announced Teva Pharmaceutical (NYSE: TEVA) buyout of Allergan Plc (NYSE: AGN), RBC Capital Markets analyst Michael Yee released a report discussing the potential for large-cap biotech companies to become buyout targets for specialty pharmaceutical companies. According to...

Biogen Inc (NASDAQ: BIIB) shares are being killed today after the company reported earnings that missed expectations and lowered guidance. Shares are trading down by more than 18 percent on Friday to below $315 at last. Michael Yee at RBC Capital Markets said that the stock may "take a bit of time...